The Commissionerate of Food Safety and Drug Control in Rajasthan has flagged seven medicines as “Not of Standard Quality” after testing from April 1 to April 15, 2026. Immediate regulatory actions are being taken across the state to prioritize public health and patient safety. Drug Controller Officers in Rajasthan have been instructed to withdraw the identified batches promptly and enforce strict actions under the Drugs and Cosmetics Act, 1940.
Commissioner Dr. T. Shubhamangala emphasized the department’s commitment to conducting regular inspections and quality surveillance to ensure the delivery of safe, effective medicines to the public and healthcare facilities. The recent testing revealed that several pharmaceutical products did not meet the required quality standards, raising concerns about their efficacy, safety, and reliability.
Among the sub-standard drugs identified are Cefixime Oral Suspension IP (LORAXIM Dry Syrup 12g/30 ml), Albendazole Tablets IP, and Ambroxol Hydrochloride, Levosalbutamol, and Guaiphenesin Drops (Istocuf-LS). These medicines, manufactured by various companies, showed deviations from the prescribed quality parameters, prompting the need for immediate action to address the deficiencies.
Methylprednisolone Tablets IP 4 mg (Methyloactive-4), Dextromethorphan HBr and Chlorpheniramine Maleate Syrup (Okuff-DX), Cefuroxime Axetil Tablets IP (EXTENSIVE-500), and Ciprofloxacin Tablets IP 500 mg are also part of the list of medicines that failed quality tests. Drug Controller Ajay Phatak has directed all healthcare facilities, pharmacies, and distributors to halt the sale, distribution, and use of these medicines.
To prevent further risks to public health, additional batches from the same manufacturers will undergo rigorous quality checks. Any non-compliance with these directives will result in strict legal actions under the Drugs and Cosmetics Act and related regulatory frameworks.
